Streetbeat News

Stock Prices

PEN

Penumbra shares are trading higher without any company-specific news.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 7:00 pm

EXC

Exelon (NASDAQ:EXC) has received 4 somewhat bullish and 1 indifferent analyst ratings in the last quarter. The company's average 12-month price target is $45.2, a decrease of 4.34% from the previous average price target of $47.25.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 7:00 pm

SILK

Oppenheimer has initiated coverage on Silk Road Medical Inc (NASDAQ:SILK) with an Outperform rating and a price target of $30. Silk Road Medical has pioneered the Transcarotid Artery Revascularization (TCAR) method for stroke prevention, leading to impressive revenue growth. However, a CMS proposal for equal reimbursement for TCAR and another method has led to a revision in SILK's projections. The company's shares are up 3.33% at $19.22.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 6:52 pm

COST

Costco Wholesale's (NYSE:COST) short percent of float has fallen 3.19% since its last report, with 4.04 million shares sold short, which is 0.91% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Costco has less short interest as a percentage of float, with an average of 3.27%.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 6:45 pm

AJG

Arthur J. Gallagher's (NYSE:AJG) short percent of float has risen 11.84% since its last report, with 1.59 million shares sold short, which is 0.85% of all regular shares available for trading. It would take traders 2.49 days to cover their short positions on average. The company's peer group average for short interest as a percentage of float is 3.12%, indicating less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 6:45 pm

ING

ING Groep's short percent of float has fallen 14.29% since its last report, with 4.23 million shares sold short, which is 0.12% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, ING Groep has less short interest.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 6:45 pm

XLRE

XLY

The Federal Reserve Beige Book reveals a moderate growth pace in the economy during July and August, but also shows signs of a slowdown in discretionary consumer spending. Consumers are increasingly resorting to borrowing to sustain their spending patterns, which could impact companies in the Consumer Discretionary Select Sector SPDR Fund (NYSE:XLY). The report also highlights challenges in the housing market, which could affect the Real Estate Select Sector SPDR Fund (NYSE:XLRE).

Portfolio Pulse from Piero Cingari

September 06, 2023 | 6:44 pm

EZGO

PFE

TARA

VINO

On Wednesday, 179 companies reached new 52-week lows. Pfizer (NYSE:PFE) was the largest company to set a new 52-week low, while Gaucho Group Holdings (NASDAQ:VINO) was the smallest. EZGO Technologies (NASDAQ:EZGO)'s stock fell the most, dropping 78.43% to reach a new 52-week low. Protara Therapeutics (NASDAQ:TARA)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 6:43 pm

AKTS

AMC

CDTX

CNM

EZGO

MRIN

PALI

U.S. stocks traded lower with the Nasdaq Composite falling more than 1%. Core & Main Inc reported a Q2 miss and narrowed its FY23 guidance. Palisade Bio, Cidara Therapeutics, and Marin Software saw their shares rise due to various positive developments. EZGO Technologies, Akoustis Technologies, and AMC Entertainment saw their shares drop due to negative news. Crude oil rose by 1.4% while gold and silver traded down.

Portfolio Pulse from Lisa Levin

September 06, 2023 | 6:41 pm

PHG

RMD

Needham has upgraded ResMed Inc (RMD) from a Hold to Buy rating with a price target of $180. ResMed's shares are down 31% since August due to concerns about the potential for GLP-1 obesity drugs to reduce demand for ResMed's sleep therapy devices and Philips' (PHG) possible re-entry into the flow generator market. However, Needham believes that both impacts will likely be small and that ResMed can sustain 5-7% revenue growth above its large-cap peers.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 6:39 pm